Dr. Reddy's Laboratories acquires injectable product portfolio from Eton Pharma
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
Dr. Reddy's Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
The acquisition is subject to customary closing conditions and necessary regulatory approvals. The financial terms of the transaction are confidential
The Toradol tablets, 10 mg brand and generic had U.S. sales of approximately US $ 16.8 million MAT for the most recent twelve months ending in March 2022 according to IQVIA
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad
Subscribe To Our Newsletter & Stay Updated